Discussion
adenomyosis, menorrhagia, anemia, dysmenorrhea
ANEMIA, DYSMENORRHEA, ADENOMYOSIS, SECONDARY, MENORRHAGIA
To our knowledge, this study is the first double-blind randomized clinical trial of mifepristone for adenomyosis treatment. This study included a placebo-controlled and multicenter design, strict randomization and masking with high adherence to treatment, and similar baseline characteristics between groups, thus providing strong evidence.The result showed that adenomyosis-associated dysmenorrhea intensity was significantly reduced after mifepristone treatment. Regardless of how severe the intensity of dysmenorrhea, the total efficacy for dysmenorrhea was satisfactory. The secondary end point assessments were all significantly improved after 12 weeks of treatment. Most patients with anemia completely recovered to levels within reference range after 12 weeks of treatment.Drug research and development in adenomyosis has been slow. GnRH-a is markedly efficient in controlling dysmenorrhea and menorrhagia and reducing uterine size for adenomyosis.As an older drug, previous evidence show that mifepristone treatment is well tolerated in long-term administration.